Literature DB >> 34800921

Beyond CD19 CAR-T cells in lymphoma.

Wingchi K Leung1, Adanma Ayanambakkam2, Helen E Heslop2, LaQuisa C Hill2.   

Abstract

Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability of CD19 CAR-T cells is limited to B cell malignancies and antigen loss can result in treatment failure, prompting the exploration of alternative targets to overcome tumor escape via CD19 antigen loss, as well as extend the CAR-T cell platform to treat Hodgkin and T cell lymphomas. This review highlights recent clinical trials testing CAR-T cell targets beyond CD19.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34800921      PMCID： PMC8901457          DOI： 10.1016/j.coi.2021.09.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  51 in total

1.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Xiaojun Qian; Ajay K Gopal; David G Maloney; Catherine G Lindgren; Yukang Lin; John M Pagel; Lihua E Budde; Andrew Raubitschek; Stephen J Forman; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

2.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Authors:  Carlos A Ramos; Barbara Savoldo; Vicky Torrano; Brandon Ballard; Huimin Zhang; Olga Dakhova; Enli Liu; George Carrum; Rammurti T Kamble; Adrian P Gee; Zhuyong Mei; Meng-Fen Wu; Hao Liu; Bambi Grilley; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

3.  CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Authors:  Jyoti Naik; Maria Themeli; Regina de Jong-Korlaar; Ruud W J Ruiter; Pino J Poddighe; Huipin Yuan; Joost D de Bruijn; Gert J Ossenkoppele; Sonja Zweegman; Linda Smit; Tuna Mutis; Anton C M Martens; Niels W C J van de Donk; Richard W J Groen
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

4.  Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Authors:  Paul M Maciocia; Patrycja A Wawrzyniecka; Brian Philip; Ida Ricciardelli; Ayse U Akarca; Shimobi C Onuoha; Mateusz Legut; David K Cole; Andrew K Sewell; Giuseppe Gritti; Joan Somja; Miguel A Piris; Karl S Peggs; David C Linch; Teresa Marafioti; Martin A Pule
Journal:  Nat Med       Date:  2017-11-13       Impact factor: 53.440

5.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Authors:  Chun-Meng Wang; Zhi-Qiang Wu; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Xiao-Hui Wang; Xiang Li; Ya-Jing Zhang; Wen-Ying Zhang; Mei-Xia Chen; Yan Zhang; Kai-Chao Feng; Yang Liu; Su-Xia Li; Qing-Ming Yang; Wei-Dong Han
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

Review 6.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

7.  Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

Authors:  Nirav N Shah; Bryon D Johnson; Dina Schneider; Fenlu Zhu; Aniko Szabo; Carolyn A Keever-Taylor; Winfried Krueger; Andrew A Worden; Michael J Kadan; Sharon Yim; Ashley Cunningham; Mehdi Hamadani; Timothy S Fenske; Boro Dropulić; Rimas Orentas; Parameswaran Hari
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

8.  Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells.

Authors:  Jia Feng; Haichan Xu; Andrew Cinquina; Zehua Wu; Qi Chen; Ping Zhang; Xingen Wang; Huiming Shan; Lei Xu; Qian Zhang; Lihua Sun; Wenli Zhang; Kevin G Pinz; Masayuki Wada; Xun Jiang; William M Hanes; Yupo Ma; Hongyu Zhang
Journal:  Stem Cell Rev Rep       Date:  2021-01-06       Impact factor: 5.739

9.  Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.

Authors:  Irene Scarfò; Maria Ormhøj; Matthew J Frigault; Ana P Castano; Selena Lorrey; Amanda A Bouffard; Alexandria van Scoyk; Scott J Rodig; Alexandra J Shay; Jon C Aster; Frederic I Preffer; David M Weinstock; Marcela V Maus
Journal:  Blood       Date:  2018-08-08       Impact factor: 25.476

10.  Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.

Authors:  D Wang; C Zeng; B Xu; J-H Xu; J Wang; L-J Jiang; Q-X Wang; C-R Li; N Wang; L Huang; Y-C Zhang; Y Xiao; J-F Zhou
Journal:  Blood Cancer J       Date:  2020-01-23       Impact factor: 11.037
View more
  1 in total

1.  A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

Authors:  Lele Miao; Juan Zhang; Zhengchao Zhang; Song Wang; Futian Tang; Muzhou Teng; Yumin Li
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.